Emapticap pegol
Based on 1 publication(s) in Google Scholar
Emapticap pegol (NOX-E36) is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36). mNOX-E36 is a murine-specific analogue of NOX-E36, an anti-MCP-1 L-RNA aptamer that was previously shown to attenuate liver fibrosis in mice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 91.38%
- No. CAS: 1390630-22-4
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Emapticap pegol
More
Actividad biológica
Spiegelmers are RNA-like molecules built from L-ribose units that are able to bind molecules such as peptides and proteins. NOX-E36, is human-specific CCL2 Spiegelmer; and mNOX-E36, is the mouse-specific CCL2 Spiegelmer[2].
NOX-E36 (1 nM) significantly inhibits CCL2-mediated migration in human monocytic leukemia cell line THP-1[2].
NOX-E36 inhibits monocyte chemotactic protein-1 (MCP-1), and blocks the inflammatory cell recruitment and differentiation of macrophages mediated by MCP-1[3].
mNOX-E36 inhibits the migration and signaling pathway activation in murine hematopoietic cells, and blocks CCL2 receptor expressing Ba/F3 cells (Ba/F3-CCR2) migration (~2000 fold than normal migration) in a dose-dependent manner[2].
mNOX-E36 abrogates the phosphorylation induced by CCL2 of AKT, ERK, p35-MAPK, respectively in mCCL2-stimulated cells (30 min)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Emapticap pegol (20 mg/kg, mNOX-E36; s.c.; three times per week, for 4 weeks) reduces albuminuria and restores the glomerular endothelial glycocalyx in diabetic mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Non-irradiated immunocompetent C57BL/6 mice injected with syngeneic AML1/ETO9a-expressing primary murine leukemia cells[2]
-
Dosage:14.4 mg/kg (mNOX-E36, Emapticap pegol of the mouse-specific CCL2 Spiegelmer)
-
Administration:Subcutaneous injection; three times per week for 3 weeks
-
Result:Abrogated this macrophage infiltration within the leukemia microenvironment.
-
Animal Model:Male Apoe KO C57BL/6J mice rendered diabetic (6-week-old)[3]
-
Dosage:20 mg/kg (mNOX-E36, Emapticap pegol of the mouse-specific CCL2 Spiegelmer)
-
Administration:Subcutaneous injection; three times per week for 4 weeks
-
Result:Reduced albumin/creatinine ratio without affecting blood glucose level and weight of mice.
Reduced heparanase and cathepsin L expression.
Chemical Information
-
No. CAS 1390630-22-4
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Emapticap pegol]
-
Synonyms
NOX-E36
-
Sequence
Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 5′-ether with RNA β-L-(G-C-A-C-G-U-C-C-C-U-C-A-C-C-G-G-U-G-C-A-A-G-U-G-A-A-G-C-C-G-U-G-G-C-U-C-U-G-C-G) 5′-[6-[[2-[(2-hydroxyacetyl)(2-hydroxyethyl)amino]acetyl]amino]hexyl hydrogen phosphate] (2:1)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Curr Res Microb Sci
Gut microbial metabolite, sphingosine-1-phosphate (S1P), drives mesangial cell phenotypic transformation and accelerates progression of IgA nephropathy via CCL2-MET-FAK pathway. [Abstract]2025 Oct 18:9:100494. PMID: 41209721
Solvente y solubilidad
H2O : 50 mg/mL (Need ultrasonic)
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (1518 KB)
Referencias
[1]. Menne J, et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant. 2017 Feb 1;32(2):307-315. [Content Brief]
[2]. Rodrigo, et al. Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia. Blood.
[3]. Boels MGS, et al. Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy. Am J Pathol. 2017 Nov;187(11):2430-2440. [Content Brief]
[4]. Lim ST, et al. Inhibition of chemokine MCP-1 with mNOX-E36 reduces scarring in a mouse model of glaucoma filtration surgery. Exp Eye Res. 2025 Nov 7:110735. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)